Background：The B lymphocyte specific CD22 antigen, also designated B-lymphocyte cell adhesion molecule （BLCAM）, sialic acid-binding Ig-like lectin 2 （Siglec-2） and Leu-14, is a type I integral membrane glycoprotein, structurally similar to other cell adhesion molecules （CAMs）, which acts as a regulator of B cell signaling. CD22 is expressed as both a cytoplasmic and membrane protein during discrete stages of B cell lymphocyte differentiation. The cytoplasmic form of CD22, expressed early in B cell development, is a useful marker for acute lymphocytic leukemia. The membrane form of CD22 is expressed in mature B cells prior to their differentiation into plasma cells.
